Tag Archives: photosensitizer

Carrier-Free, Amorphous Verteporfin Nanodrug for Enhanced Photodynamic Cancer Therapy and Brain Drug Delivery

Published in: Advanced Science Authors: John A. Quinlan, Collin T. Inglut, Payal Srivastava, Idrisa Rahman, Jillian Stabile, Brandon Gaitan, Carla Arnau Del Valle, Kaylin Baumiller, Anandita Gaur, Wen-An Chiou, Baktiar Karim, Nina Connolly, Robert W. Robey, Graeme F. Woodworth, Michael M. Gottesman, Huang-Chiao Huang University of Maryland  Published in: Advanced Science Authors: John A. Quinlan, Collin T. Inglut, Payal Srivastava, Idrisa Rahman, Jillian Stabile, Brandon Gaitan, Carla Arnau Del Valle, Kaylin Baumiller, Anandita Gaur, Wen-An Chiou, Baktiar Karim, Nina Connolly, Robert W. Robey, Graeme F. Woodworth, Michael M. Gottesman, Huang-Chiao Huang University of Maryland Glioblastoma (GBM) is hard to treat due to cellular invasion into functioning brain tissues, limited drug delivery, and evolved treatment resistance. Recurrence is nearly universal even after surgery, chemotherapy, and radiation. Photodynamic therapy (PDT) involves photosensitizer administration followed by light activation to generate reactive oxygen species at tumor sites, thereby killing cells or Continue reading →

Co-Packaged PARP inhibitor and photosensitizer for targeted photo-chemotherapy of 3D ovarian cancer spheroids

Published in: Cell & Bioscience Authors: Aaron Sorrin, Anika Dasgupta, Kathryn McNaughton, Carla Arnau Del Valle, Keri Zhou, Cindy Liu, Dana M. Roque & Huang Chiao Huang Within the last decade, poly(ADP-ribose) polymerase inhibitors (PARPi) have emerged in the clinic as an effective treatment for numerous malignancies. Preclinical data have demonstrated powerful combination effects of PARPi paired with photodynamic therapy (PDT), which involves light-activation of specialized dyes (photosensitizers) to stimulate cancer cell death through reactive oxygen species generation. In this study, a novel combination strategy was Continue reading →

Transient fluid flow improves photoimmunoconjugate delivery and photoimmunotherapy efficacy

Published in: iScience Authors: Aaron J. Sorrin, Keri Zhou, Katherine May, Cindy Liu, Kathryn McNaughton, Idrisa Rahman, Barry J. Liang, Imran Rizvi, Dana M. Roque, Huang-Chiao Huang    Published in: iScience Authors: Aaron J. Sorrin, Keri Zhou, Katherine May, Cindy Liu, Kathryn McNaughton, Idrisa Rahman, Barry J. Liang, Imran Rizvi, Dana M. Roque, Huang-Chiao Huang   The study showed that fluid flow induced shear stress increased the photocytotoxicity of different photosensitizers tested (BPD, PIC, PIC-coated liposome) against ovarian cancer cells. The cellular delivery of photosensitizers doubled compared to static conditions. Modulight laser was used for PDT activation together with photosensitizer(s). Circulating drugs in the peritoneal cavity is an effective strategy for advanced ovarian Continue reading →

Pharmaceutical nanotechnology applied to phthalocyanines for the promotion of antimicrobial photodynamic therapy: A literature review

Published in: Photodiagnosis and Photodynamic Therapy Authors: Luciana Betzler de Oliveira de Siqueira, Ana Paula dos Santos Matos, Marcio Robert Mattos da Silva, Suvene Rocha Pinto, Ralph Santos-Oliveira, Eduardo Ricci-Júnior  Published in: Photodiagnosis and Photodynamic Therapy Authors: Luciana Betzler de Oliveira de Siqueira, Ana Paula dos Santos Matos, Marcio Robert Mattos da Silva, Suvene Rocha Pinto, Ralph Santos-Oliveira, Eduardo Ricci-Júnior   Phthalocyanines are photosensitizers activated by light at a specific wavelength in the presence of oxygen and act through the production of Reactive Oxygen Species, which simultaneously attack several biomolecular targets in the pathogen agent and, therefore, have multiple and variable action sites. This nonspecific action site bypasses conventional resistance mechanisms. Antimicrobial Photodynamic Therapy (aPDT) is Continue reading →

In vitro illumination using ML8500: osmium-based anticancer photosensitizer with highest hypoxic activity reported to date

  Sherri McFarland discussing how ML8500 is supporting her research   Study protocol to determine wavelength, fluence, and irradiance activities of Os-4T:   Key observations Illumination parameters significantly affected the phototoxicity of Os-4T. The green light (525 nm) was more effective than the red light (630 nm) at lower fluences, while the maximal potency was achieved at both wavelengths when using fluences higher than 100 J/cm2. Irradiance affected the potency with both the red and the green light that were more effective when lower irradiances Continue reading →Customer case Research by: University of Texas at Arlington, US. One of the leading groups in photoactive drug discovery. Developed first clinical-level rubidium-based PS (TLD-1433), now in Theralase-sponsored Phase 2 trials for bladder cancer. Modulight products: ML8500 (445 nm, 525 nm, 630 nm, 753 nm, 810 nm) Laser use: Photoactive drug discovery Link to the study: Prof. Sherri McFarland Research topics: Medicinal inorganic chemistry and drug discovery. Special interest in the synthesis of novel transition metal complexes and studying their interactions with light for the purpose Continue reading →

Breaking the barrier: an osmium photosensitizer with unprecedented hypoxic phototoxicity for real world photodynamic therapy

Published in: Chemical Science Authors: John A. Roque III, Patrick C. Barrett, Houston D. Cole, Liubov M. Lifshits, Ge Shi, Susan Monro, David von Dohlen, Susy Kim, Nino Russo, Gagan Deep, Colin G. Cameron, Marta E. Alberto, Sherri A. McFarland    Published in: Chemical Science Authors: John A. Roque III, Patrick C. Barrett, Houston D. Cole, Liubov M. Lifshits, Ge Shi, Susan Monro, David von Dohlen, Susy Kim, Nino Russo, Gagan Deep, Colin G. Cameron, Marta E. Alberto, Sherri A. McFarland   ML8500 was used for specialized dosimetry studies in the development of the osmium-based PS using similar drug development strategy as for the analogous Ru(II) series that resulted in TLD1433 (first metal complex in clinical trials). The Os-compound approaches the ideal properties with multi-wavelength activation Continue reading →

Light Sources and Dosimetry Techniques for Photodynamic Therapy

Published in: Photochemistry and Photobiology Authors: Michele M. Kim, Arash Darafsheh  Published in: Photochemistry and Photobiology Authors: Michele M. Kim, Arash Darafsheh   Effective treatment delivery in photodynamic therapy (PDT) requires coordination of the light source, the photosensitizer, and the delivery device appropriate to the target tissue. Lasers, light-emitting diodes (LEDs), and lamps are the main types of light sources utilized for PDT applications. The choice of light source depends on the target location, photosensitizer used, and light dose to be delivered. Geometry of minimally accessible areas also plays a role in deciding light applicator type. Continue reading →

Porphyrin-lipid assemblies and nanovesicles overcome ABC transporter-mediated photodynamic therapy resistance in cancer cells

Published in: Cancer Letters Authors: Yan Baglo, Barry J. Liang, Robert W. Robey, Suresh V. Ambudkar, Michael M. Gottesman, Huang-Chiao Huang    Published in: Cancer Letters Authors: Yan Baglo, Barry J. Liang, Robert W. Robey, Suresh V. Ambudkar, Michael M. Gottesman, Huang-Chiao Huang   They have used laser to study PDT resistance mechanisms by activating BPD photosensitizer in cancer cell lines and subsequently determining the cell viabilities. The lipidation of BPD is shown to decrease its efflux from cells and increase PDT effectiveness.   Read the article here